Researchers propose new approach to identify genetic mutations in men with prostate cancer
ANN ARBOR, Michigan – Scientists have had limited success at identifying specific inherited genes associated with prostate cancer, despite the fact that it is one of the most common non-skin cancers among men.
Researchers studied prostate cancer patients with multiple cancer diagnoses, many who would not be recommended for genetic tests following current guidelines, to identify genetic mutations that may influence cancer treatment and cancer risk assessment for family members. Their findings are reported in the June issue of the journal Cancer.
“We commonly use a combination of a patient’s personal and family cancer histories to identify those individuals who may have a mutation in a gene that predisposes that individual to developing cancers,” says Patrick Pilié, M.D., medical oncology fellow at the University of Texas MD Anderson Cancer Center.
“Testing for hereditary cancers impacts not only the patient with cancer but also potentially the cancer screening and health outcomes of their entire family, but many prostate cancer patients do not meet the current guidelines to test for genetic cancer heritability,” he says.
Pilié was part of a research team led by Kathleen Cooney, M.D. Cooney performed the work while at the University of Michigan. She proposed a strategy to identify germline mutations in men selected for the study based on their clinical history, not their family history.
The study was highly selective, including 102 patients who had been diagnosed with prostate cancer and at least one additional primary cancer, such as melanoma, pancreatic cancer, testicular cancer or Hodgkin lymphoma.
The researchers examined the frequency of harmful germline mutations in this group of men. These mutations originate on either the egg or sperm and become incorporated into the DNA of every cell in the body of the resulting offspring.
Using next generation sequencing, the researchers found that 11 percent of the patients had a disease-causing mutation in at least one cancer-predisposing gene, which suggests these genetic variations contributed to their prostate cancer. The researchers found no difference in cancer aggressiveness or age of diagnosis compared to patients without these mutations.
In addition, co-investigator Elena Stoffel, M.D., director of the Cancer Genetics Clinic at the University of Michigan Rogel Cancer Center, reviewed personal and family histories from each patient to determine whether they would meet clinical genetic testing guidelines. The majority of the men in the study, 64 percent, did not meet current criteria to test for hereditary cancer based on personal or family history.
The findings suggest that there are men with heritable prostate cancer-predisposing mutations that are not eligible for genetic screening under current guidelines.
The majority of harmful mutations identified were in genes involved in DNA repair. The mutations appear to prevent the DNA from healing itself, which can lead to a predisposition for cancer.
This result is also beneficial because a class of drugs called PARP inhibitors have a better success rate in treating cancers with the underlying gene mutation associated with DNA repair.
This is a small pilot study rather than a broader epidemiological survey, and it consists of a highly specific subset of patients. Therefore, it is premature to generalize these findings to the broader population.
The 102 patients included in the study were identified from the University of Michigan’s Prostate Cancer Genetics Project, which registers patients who are diagnosed with prostate cancer before age 55 or who have a first- or second-degree relative with prostate cancer. In addition, the research team identified patients from the University of Michigan’s Cancer Genetics Registry, which includes individuals with personal or family history suggestive of a hereditary risk of cancer.
“Our findings are in line with those of other studies, suggesting that approximately 1 in 10 men with advanced prostate cancer harbors a genetic variant associated with increased cancer risk,” Stoffel says. “While family history is an important tool, there may be better ways to identify patients with genetic risk.”
Future studies with larger sample sizes will include sequencing of tumors that will allow investigators to more carefully explore the different features associated with tumors that arise in individuals with germline mutations.
“This approach will help us identify patients at greater risk for aggressive prostate cancer so they can seek earlier screening while pre-symptomatic,” Cooney says.
This research was supported by a National Cancer Institute Prostate Cancer Specialized Program of Research Excellence (SPORE) grant to the University of Michigan (P50 CA186786) and the University of Michigan Rogel Cancer Center Sequencing Core.
Courtesy of University of Utah Health